We just love seeing our #PartnersInPrevention initiatives in action! Scenes from #4thofJuly fun in Friendswood parks — one of several free sunscreen dispensers, part of the Sun Safe City program partnership with IMPACT Melanoma, the City of Friendswood, and Castle Biosciences. #PracticeSafeSkin #NoSunForBabies #CatchShade
Castle Biosciences, Inc.
Biotechnology Research
Friendswood, Texas 11,814 followers
Improving health through innovative tests that guide patient care
About us
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company focused on transforming disease management by keeping people first—the patients who benefit from the information that our advanced diagnostic tests provide, the clinicians who use our tests to guide disease management decisions, our talented and valued employees, and our investors. Our innovative portfolio of commercial and pipeline tests targets unmet clinical need along the patient care continuum. We currently market six proprietary tests designed to answer clinical questions and address treatment plan challenges facing physicians in dermatologic cancers, uveal melanoma, Barrett’s esophagus, and mental health. https://castletestinfo.com Our test for invasive cutaneous melanoma, DecisionDx®-Melanoma, is a proprietary gene expression profile (GEP) test that uses an individual patient’s tumor biology to predict the risk of metastasis or recurrence, as well as the risk of sentinel lymph node positivity, independent of traditional staging factors. http://bit.ly/DDx-Melanoma DecisionDx®-SCC is our GEP test that predicts the risk of metastasis in patients with cutaneous squamous cell carcinoma, who have one or more risk factors. https://bit.ly/DDx-SCC DecisionDx®-UM, the standard of care in uveal melanoma staging, is our GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer. https://bit.ly/DDx-UM Our comprehensive diagnostic offering — myPath® Melanoma and DiffDx®-Melanoma — provides a highly accurate, objective result to aid dermatopathologists and dermatologists in characterizing suspicious pigmented lesions. https://bit.ly/myPathDiffDx TissueCypher® Barrett’s Esophagus is the world’s first precision medicine test designed to predict future development of esophageal cancer in patients with Barrett’s esophagus. https://tissuecypher.com Castle Biosciences is based in Friendswood, TX and has laboratory operations in Phoenix, AZ, and Pittsburgh, PA.
- Website
-
http://www.castlebiosciences.com
External link for Castle Biosciences, Inc.
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Friendswood, Texas
- Type
- Public Company
- Founded
- 2008
- Specialties
- Diagnostic Cancer Testing, Uveal Melanoma, Cutaneous Melanoma, Melanoma, Skin Cancer, Next Gen Sequencing, Cutaneous Squamous Cell Carcinoma, Gene Expression Profile Tests, Barrett's Esophagus, Esophageal Adenocarcinoma, and Dermatologic Cancer
Locations
-
Primary
505 S Friendswood Dr
Suite 401
Friendswood, Texas 77546, US
-
3737 N 7th St
Suite 160
Phoenix, Arizona 85014, US
-
235 William Pitt Way
B1
Pittsburgh, Pennsylvania 15238, US
Employees at Castle Biosciences, Inc.
Updates
-
Castle wishes you a very happy Independence Day🇺🇸! Enjoy food, fun, family, and freedom and as always, #PracticeSafeSun☀️. CHEERS! #4thofJuly
-
-
Castle Biosciences, Inc. reposted this
🎉 #IMPACTMelanoma is excited to introduce #PhoenixAZ residents to the recently added free sunscreen dispensers now available at splash-pads across the city. 🏆 These dispensers are part of a pilot program in #Phoenix made possible by our #PartnersInPrevention, Castle Biosciences, Inc., and Phoenix Parks and Recreation. The project was initiated by University of Arizona College of Medicine-Phoenix student, Rini Desai. ✨ Be sure to try to spot the new dispensers as you head to tonight’s Light Up The Sky event at American Family Fields. Learn about other #PartnerInPrevention projects across the country: https://bit.ly/4aoBBN9
-
-
Frank is in Times Square! Congratulations once more to our inimitable CFO, Frank Stokes, for being named a Top CFO in Houston, and big thanks to Nasdaq for showcasing him and his awesomeness in the Big Apple! #FrankStokesSuperstar⭐ #Top25CFOs #Nasdaq
-
-
Castle Biosciences, Inc. reposted this
Kudos to our partners in prevention, the City of Friendswood, TX and Castle Biosciences, Inc., who are spreading awareness & sunscreen throughout the city!🧴 👏 Read their story: https://bit.ly/3V43HHR #ImpactMelanoma #PracticeSafeSkin
-
-
Did you know? UV exposure that leads to sunburn has proven to play a strong role in developing #melanoma, the most dangerous form of skin cancer. According to The Skin Cancer Foundation, UV rays that damage skin cells can also alter a gene that suppresses tumors, raising the risk of sun-damaged skin cells developing into #SkinCancer. #PracticeSafeSun☀️: cover up, seek shade, wear sunscreen, and don't forget your 👀 — wear sunglasses! #UVSafetyAwarenessMonth #ShareTheFacts #CastleCares
-
-
Castle Biosciences, Inc. reposted this
Listen to Dr. Desiree Ratner, a Mohs surgeon, discuss how she utilizes DecisionDx-SCC by Castle Biosciences, Inc. to improve treatment decisions for SCC, including when to refer patients to radiation oncology.
-
"I'm really connected to the why." Luke Barnett, Senior Medical Liaison, weighs in on why he loves working at Castle. "To do work that feels like it matters makes me feel like my job means something vs. sometimes you don't understand the why, and I'm really connected to the why." #WhyCastle #CastleCulture #TopWorkplaces #CastleCareers #CultureExcellence
-
June is National #CancerSuvivorsMonth. We celebrate Morgan England, a stage III melanoma survivor, who advocated to take the DecisionDx-Melanoma test, the results of which she says continue to help reduce her anxiety and provide confidence about her future. https://hubs.la/Q02DsW-60 DecisionDx-Melanoma is Castle's gene expression profile (GEP) test that analyzes a patient's unique tumor biology to predict their personal risk of recurrence and/or metastasis. It can help to improve prognostic accuracy, better inform management decisions, and positively impact outcomes.
Be Your Own Advocate: Morgan England, Stage III Melanoma Survivor, Shares Her Story
https://www.youtube.com/
-
Castle is proud to collaborate with iTASC, who provides treatment access for underserved, uninsured skin cancer patients, regardless of financial resources, by partnering with organizations to provide free, quality specialized skin cancer treatment. Shawn Massie, who utilized iTASC's program in Dayton, Ohio, talks about his experience: https://lnkd.in/gKYsHEsi Learn more about iTASC at https://itasc.org/. Skin Cancer Treatment:501(C)(3)
Skin Cancer iTASC patient
https://www.youtube.com/